Regeneron Pharmaceuticals, Inc. (REGN)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS75886F1075
954.71 USD
+0.37% today Updated 13 Nov 2026 16:32
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Regeneron Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:32. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
28 Jan 2027
in 76 days · 08:00 · estimate 25.39
Last results
20.07 vs 16.25 estimated
30 Oct 2026 · Beat +23.5%
Beat the estimate
10 of 12
2 missed · 0 in line · 6 beats in a row
Average surprise
+14.7%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 28 Jan 2027 08:00 | 25.39 | — | — | Upcoming |
| 30 Oct 2026 06:00 | 16.25 | 20.07 | +23.5% | Beat |
| 30 Jul 2026 06:00 | 10.21 | 14.29 | +40.0% | Beat |
| 29 Apr 2026 06:00 | 8.90 | 9.47 | +6.4% | Beat |
| 30 Jan 2026 06:00 | 10.75 | 11.44 | +6.4% | Beat |
| 28 Oct 2025 06:00 | 9.64 | 11.83 | +22.7% | Beat |
| 01 Aug 2025 06:00 | 8.44 | 12.89 | +52.7% | Beat |
| 29 Apr 2025 06:00 | 8.48 | 8.22 | -3.0% | Miss |
| 04 Feb 2025 06:00 | 11.19 | 12.07 | +7.8% | Beat |
| 31 Oct 2024 06:00 | 11.70 | 12.46 | +6.5% | Beat |
| 01 Aug 2024 06:00 | 10.62 | 11.56 | +8.8% | Beat |
| 02 May 2024 06:00 | 10.10 | 9.55 | -5.4% | Miss |
| 02 Feb 2024 06:00 | 10.75 | 11.86 | +10.4% | Beat |
| 02 Nov 2023 06:00 | 10.78 | 11.59 | +7.6% | Beat |
| 03 Aug 2023 06:00 | 9.90 | 10.24 | +3.5% | Beat |
| 04 May 2023 06:00 | 9.56 | 10.09 | +5.6% | Beat |
| 03 Feb 2023 06:00 | 10.01 | 12.56 | +25.5% | Beat |
| 03 Nov 2022 06:00 | 9.48 | 11.14 | +17.6% | Beat |
| 03 Aug 2022 06:00 | 8.76 | 9.77 | +11.6% | Beat |
| 04 May 2022 06:00 | 9.80 | 11.49 | +17.3% | Beat |
| 04 Feb 2022 06:00 | 20.30 | 23.72 | +16.9% | Beat |
| 04 Nov 2021 06:00 | 9.94 | 15.37 | +54.7% | Beat |
| 05 Aug 2021 06:00 | 17.71 | 25.80 | +45.7% | Beat |
| 06 May 2021 06:00 | 8.68 | 9.89 | +14.0% | Beat |
| 05 Feb 2021 06:00 | 8.29 | 9.53 | +15.0% | Beat |
| 05 Nov 2020 06:00 | 6.99 | 8.36 | +19.6% | Beat |
| 05 Aug 2020 06:00 | 5.97 | 7.16 | +20.0% | Beat |
| 05 May 2020 07:00 | 6.09 | 6.60 | +8.5% | Beat |
| 06 Feb 2020 06:00 | 7.17 | 7.50 | +4.6% | Beat |
| 05 Nov 2019 06:00 | 6.40 | 6.67 | +4.3% | Beat |
| 06 Aug 2019 06:00 | 5.42 | 6.02 | +11.2% | Beat |
| 07 May 2019 06:00 | 5.52 | 4.45 | -19.4% | Miss |
| 06 Feb 2019 06:00 | 5.60 | 6.84 | +22.1% | Beat |
| 06 Nov 2018 06:00 | 5.06 | 5.87 | +15.9% | Beat |
| 02 Aug 2018 06:00 | 4.68 | 5.45 | +16.4% | Beat |
| 03 May 2018 06:00 | 4.34 | 4.67 | +7.5% | Beat |
| 08 Feb 2018 06:00 | 4.57 | 5.23 | +14.4% | Beat |
| 08 Nov 2017 06:00 | 3.82 | 3.99 | +4.4% | Beat |
| 03 Aug 2017 06:00 | 3.18 | 4.17 | +31.0% | Beat |
| 04 May 2017 06:00 | 3.07 | 2.92 | -4.8% | Miss |
| 09 Feb 2017 07:00 | 3.05 | 3.04 | -0.3% | In line |
| 04 Nov 2016 06:00 | 2.70 | 3.13 | +16.0% | Beat |
| 04 Aug 2016 06:00 | 2.65 | 2.82 | +6.4% | Beat |
| 05 May 2016 06:00 | 2.55 | 2.57 | +0.8% | In line |
| 09 Feb 2016 06:00 | 3.36 | 2.83 | -15.8% | Miss |
| 04 Nov 2015 06:00 | 3.20 | 3.47 | +8.3% | Beat |
| 04 Aug 2015 06:00 | 2.78 | 2.89 | +4.0% | Beat |
| 07 May 2015 06:00 | 2.69 | 2.88 | +7.2% | Beat |
| 10 Feb 2015 06:00 | 2.83 | 2.79 | -1.5% | Miss |
| 04 Nov 2014 06:00 | 2.57 | 2.52 | -2.1% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 14.3B | +1.0% | 4.5B | 31.4% | 41.48 | +8.2% | 3.8B |
| 2024 | 14.2B | +8.3% | 4.4B | 31.1% | 38.34 | +10.3% | 3.5B |
| 2023 | 13.1B | +7.8% | 4B | 30.1% | 34.77 | -9.0% | 3.7B |
| 2022 | 12.2B | — | 4.3B | 35.6% | 38.22 | — | 3.4B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 922.35 | 981.55 | 898.29 | 954.71 | +5.57% | 3,967,170 | |
| 02 Nov 2026 – 06 Nov 2026 | 927.22 | 991.73 | 887.04 | 904.35 | -2.54% | 6,783,600 | |
| 26 Oct 2026 – 30 Oct 2026 | 812.31 | 935.35 | 796.61 | 927.89 | +15.26% | 5,344,000 | |
| 19 Oct 2026 – 23 Oct 2026 | 792.59 | 825.52 | 780.83 | 805.02 | +1.81% | 3,074,000 | |
| 12 Oct 2026 – 16 Oct 2026 | 748.67 | 809.49 | 743.57 | 790.74 | +5.92% | 3,578,500 | |
| 05 Oct 2026 – 09 Oct 2026 | 734.37 | 753.68 | 722.02 | 746.54 | +1.54% | 2,902,500 | |
| 28 Sep 2026 – 02 Oct 2026 | 778.09 | 780.95 | 726.02 | 735.20 | -6.71% | 4,483,200 | |
| 21 Sep 2026 – 25 Sep 2026 | 786.03 | 813.53 | 779.96 | 788.04 | +0.41% | 3,220,400 | |
| 14 Sep 2026 – 18 Sep 2026 | 791.98 | 798.84 | 769.57 | 784.85 | +0.43% | 4,690,000 | |
| 08 Sep 2026 – 11 Sep 2026 | 814.36 | 821.17 | 780.81 | 781.49 | -5.59% | 2,148,800 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock? (opens in a new tab) Zacks · 12 Nov 2026 16:21
- Regeneron Pharmaceuticals (REGN) Reports Early MASLD Trial Data With 62% Liver Fat Normalization (opens in a new tab) Simply Wall St. · 12 Nov 2026 08:11
- Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? (opens in a new tab) 24/7 Wall St. · 10 Nov 2026 18:17
- Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80% (opens in a new tab) MarketBeat · 10 Nov 2026 17:15
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 16:01
- Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD (opens in a new tab) 10 Nov 2026 15:00
- Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients (opens in a new tab) Benzinga · 10 Nov 2026 11:02
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH - Slideshow (opens in a new tab) SeekingAlpha · 10 Nov 2026 10:34
- Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery (opens in a new tab) 09 Nov 2026 14:31
- Regeneron Pharmaceuticals (REGN) Extends BARDA Deal As Libtayo Long Term Data Holds Up (opens in a new tab) Simply Wall St. · 08 Nov 2026 14:10
- Huda Y Zoghbi At Regeneron Pharmaceuticals Executes Options Exercise, Realizing $3.88M (opens in a new tab) Benzinga · 06 Nov 2026 11:01
- Mary Tyler Moore Vision Initiative Welcomes Regeneron and Adaptive Sensory Technology to Its Consortium (opens in a new tab) 05 Nov 2026 16:06
- Strategic Exercise: Christine A Poon Decides To Exercise Options Worth $4.39M At Regeneron Pharmaceuticals (opens in a new tab) Benzinga · 05 Nov 2026 11:01
- At Regeneron Pharmaceuticals, George L Sing Chooses To Exercise Options, Resulting In $8.53M (opens in a new tab) Benzinga · 05 Nov 2026 11:01
- Is Regeneron Stock Riskier Than It Looks? (opens in a new tab) Trefis · 05 Nov 2026 10:36
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 951.19 USD
- Market cap
- 98.4B
- Dividend yield
- 0.40%
- Payout ratio
- 8%
- Last dividend
- 0.9400 USD · 20 Nov 2026
- Next ex-dividend date
- 20 Nov 2026
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 18 Aug 2026 | 0.9400 USD |
| 20 May 2026 | 0.9400 USD |
| 20 Feb 2026 | 0.9400 USD |
| 20 Nov 2025 | 0.8800 USD |
| 3 older dividends: create a free account to see them | |
Why this score
Similar shares
Follow REGN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.